In a report released today, Jeff Jones from Oppenheimer maintained a Hold rating on AN2 Therapeutics, Inc. (ANTX – Research Report). The company’s shares closed yesterday at $2.31.
Jones covers the Healthcare sector, focusing on stocks such as Ventyx Biosciences, Corbus Pharmaceuticals, and PMV Pharmaceuticals. According to TipRanks, Jones has an average return of 27.8% and a 43.48% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AN2 Therapeutics, Inc. with a $5.50 average price target.
ANTX market cap is currently $68.91M and has a P/E ratio of -0.82.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AN2 Therapeutics, Inc. (ANTX) Company Description:
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Read More on ANTX:
